Evidence map›Paper›PMID 26260145›Full record

ReviewNature reviews. Endocrinology2015

Metabolic functions of FABPs--mechanisms and therapeutic implications.

Gökhan S Hotamisligil, David A Bernlohr

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 393 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
393citing papers in PubMed, 4 pooled it
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

393 citing papers in PubMed, 4 syntheses or guidelines pooled it, 701 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Lipid homeostasis in diabetic kidney disease.International journal of biological sciences · 2024
    Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Article
  18. CD8MedComm · 2026
    Review
  19. Article
  20. Article

333 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Gökhan S HotamisligilDepartment of Genetics and Complex Diseases and Sabri Ülker Center, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA.
David A BernlohrDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 321 Church Street SE, Minneapolis, MN 55455, USA.
University of Minnesota · US

Funding

LIPID BINDING PROTEINS IN OBESITY/DIABETES SYNDROMESR01DK053189 · NIDDK · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BERNLOHR, DAVID A · 1998 to 2020
$5.6M
Lipids, Inflammation and Insulin ActionR01DK064360 · NIDDK · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HOTAMISLIGIL, GOKHAN S · 2004 to 2013
$3.7M
Lipid Binding Proteins in Obesity and Diabetes SyndromesR56DK053189 · NIDDK · UNIVERSITY OF MINNESOTA · PI BERNLOHR, DAVID A · 2011 to 2017
$300k
Lipids, Inflammation and Insulin ActionR56DK064360 · NIDDK · HARVARD SCHOOL OF PUBLIC HEALTH · PI HOTAMISLIGIL, GOKHAN S · 2008 to 2008
$163k
NIDDK NIH HHS DK053189NIDDK NIH HHS DK064360NIDDK NIH HHS R01 DK053189NIDDK NIH HHS R01 DK064360NIDDK NIH HHS R56 DK053189NIDDK NIH HHS R56 DK064360
6 · The paper itself

Abstract

Intracellular and extracellular interactions with proteins enables the functional and mechanistic diversity of lipids. Fatty acid-binding proteins (FABPs) were originally described as intracellular proteins that can affect lipid fluxes, metabolism and signalling within cells. As the functions of this protein family have been further elucidated, it has become evident that they are critical mediators of metabolism and inflammatory processes, both locally and systemically, and therefore are potential therapeutic targets for immunometabolic diseases. In particular, genetic deficiency and small molecule-mediated inhibition of FABP4 (also known as aP2) and FABP5 can potently improve glucose homeostasis and reduce atherosclerosis in mouse models. Further research has shown that in addition to their intracellular roles, some FABPs are found outside the cells, and FABP4 undergoes regulated, vesicular secretion. The circulating form of FABP4 has crucial hormonal functions in systemic metabolism. In this Review we discuss the roles and regulation of both intracellular and extracellular FABP actions, highlighting new insights that might direct drug discovery efforts and opportunities for management of chronic metabolic diseases.

Indexed as

AnimalsFatty Acid-Binding ProteinsGene ExpressionHumansInflammationLipid MetabolismMiceFABP4 protein, humanFatty Acid-Binding Proteins

Identifiers

PMID26260145
PMCPMC4578711
OpenAlexW1872721533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.